← Search & browse all drugs

carisoprodol

M03BA02

Forms & Strengths

Tablet: 250 mg
Tablet: 350 mg

Adult Dosing

250 mg to 350 mg orally three times daily and at bedtime
Duration of treatment should be acute (up to 2-3 weeks)

Pediatric Dosing

Safety and effectiveness in pediatric patients under 16 years of age have not been established

Indications

As an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions

Mechanism of Action

Central nervous system depressant; acts at the level of the spinal cord and descending reticular formation of the brain to produce sedation and alter interneuronal activity, reducing pain and relaxing skeletal muscle
Metabolized to meprobamate, which has anxiolytic and sedative properties

Contraindications

Acute intermittent porphyria
Known hypersensitivity to carisoprodol or meprobamate

Adverse Reactions

Drowsiness
Dizziness
Headache
Vertigo
Tachycardia
Orthostatic hypotension
Nausea
Vomiting
Epigastric distress

Drug Interactions

Central nervous system depressants (e.g., alcohol, opioids, benzodiazepines, tricyclic antidepressants): May potentiate CNS depression and impair psychomotor performance
CYP2C19 inhibitors (e.g., omeprazole, fluvoxamine): May increase carisoprodol concentrations
CYP2C19 inducers (e.g., rifampin, St. John's wort): May decrease carisoprodol concentrations and increase meprobamate concentrations

Curated Content: Needs Vetting Before Put to Clinical Use